Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Menopause International

• Publication date

  2009-03-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1258/mi.2009.009004PMID 19237618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

  2008cited by this paper
• Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.

  2008cited by this paper
• HRT in the early menopause: scientific evidence and common perceptions

  2008cited by this paper
• Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

  2008cited by this paper
• Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

  2007cited by this paper
• Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial

  2007cited by this paper
• Health related quality of life in different states of breast cancer

  2007cited by this paper
• Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.

  2007cited by this paper
• Faculty Opinions recommendation of Venous thrombosis and conjugated equine estrogen in women without a uterus.

  2006cited by this paper
• Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

  2006cited by this paper
• Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial

  2006cited by this paper
• Health and Quality of Life Outcomes

  2006cited by this paper
• Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.

  2006cited by this paper
• Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

  2005cited by this paper
• Costs and quality of life associated with osteoporosis-related fractures in Sweden

  2005cited by this paper
• The health status of the Dutch population as assessed by the EQ-6D

  2005cited by this paper
• Estrogen plus progestin and risk of venous thrombosis.

  2005cited by this paper
• Estrogen plus progestin and colorectal cancer in postmenopausal women.

  2004cited by this paper
• Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study).

  2004cited by this paper
• Excess mortality after hospitalisation for vertebral fracture

  2004cited by this paper
• Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial

  2004cited by this paper
• Mortality after osteoporotic fractures

  2004cited by this paper
• Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.

  2004cited by this paper
• Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.

  2004cited by this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cited by this paper
• The components of excess mortality after hip fracture.

  2003cited by this paper
• Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

  2003cited by this paper
• Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

  2003cited by this paper
• Breast cancer and hormone-replacement therapy: the Million Women Study.

  2003cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Long-Term Risk of Osteoporotic Fracture in Malmö

  2000cited by this paper
• The impact of hormone replacement therapy on quality of life and willingness to pay

  1999cited by this paper
• Mortality after all major types of osteoporotic fracture in men and women: an observational study.

  1999cited by this paper
• Variations in population health status: results from a United Kingdom national questionnaire survey

  1998cited by this paper
• Lifetime Risk of Hip Fractures is Underestimated

  1998cited by this paper
• Epidemiology of fractures in 15,000 adults: the influence of age and gender.

  1998cited by this paper
• Prediction of coronary heart disease using risk factor categories.

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.

  1998cited by this paper
• Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.

  1996cited by this paper
• Hormone replacement therapy in a risk-benefit perspective.

  1996cited by this paper
• Cost-effectiveness of fracture prevention in established osteoporosis.

  1996cited by this paper
• Outcome and time course of recovery in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study.

  1995cited by this paper
• Measuring the impact of menopausal symptoms on quality of life.

  1993cited by this paper
• Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

  1992cited by this paper
• What is the true mortality of hip fractures?

  1991cited by this paper
• Economic Duration Data and Hazard Functions

  1988cited by this paper

• Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis

  2023cites this paper
• A cross-sectional study of symptoms and health-related quality of life in menopausal-aged women in China

  2023cites this paper
• Hormone therapy for postmenopausal osteoporosis management

  2021cites this paper
• Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?

  2020cites this paper
• Prescription of hormone replacement therapy prior to and after the diagnosis of gynecological cancers in German patients

  2020cites this paper
• Chinese and Indian women’s experience with alternative medications for menopause related symptoms: A qualitative analysis

  2017cites this paper
• Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations

  2017influential citation
• Use of Ursodeoxycholic Acid on Post-menopausal Obesity, Hepatic steatosis and Plasma Profile as an Alternative Treatment for Hormone Replacement Therapy

  2015cites this paper
• 폐경기 여성들의 혈관운동증상 관리에 대한 지불의사금액과 영향요인 분석

  2014cites this paper
• Cost-effectiveness analysis of hormone replacement therapy for menopausal women in Serbia

  2012cites this paper
• Hormone replacement therapy

  2012cites this paper
• In vivo estrogenic activity of Nigella sativa different extracts using vaginal cornification assay

  2011cites this paper
• Menopause, evolution and changing cultures

  2009cites this paper